Navigation Links
WestPark Capital, Inc. Announces $2.6 Million IsoRay Offering

LOS ANGELES, December 2, 2011 /PRNewswire/ -- WestPark Capital, Inc. announced the completion of a public offering for IsoRay, Inc. (NYSE Amex: ISR). A total of 2,817,988 shares of common stock and warrants to purchase up to 563,598 shares of common stock were sold, generating gross proceeds of $2,592,549 in the offering. Proceeds from the offering will be used to fund new applications for IsoRay's Cesium-131 technology to treat lung, head and neck, breast and brain cancers, and for working capital and general corporate purposes. WestPark Capital, Inc. acted as lead manager for the offering. This offering was originated through Tekesta Capital Partners, a division of WestPark Capital, Inc.

This press release does not constitute an offer to sell or the solicitation of offers to buy any security and shall not constitute an offer, solicitation, or sale of any security in any jurisdiction in which such offer, solicitation, or sale would be unlawful. The offering was made only by prospectus. A prospectus supplement relating to the common stock and warrants issued in the offering has been declared effective by the Securities and Exchange Commission. Copies of the prospectus supplement and accompanying base prospectus may be obtained at the SEC website at, or via written request to WestPark Capital, Inc., 1900 Avenue of the Stars, Suite 310, Los Angeles, California 90067.

About WestPark Capital, Inc.

WestPark Capital is a leading investment banking and securities brokerage firm serving the needs of private and public growth companies worldwide. WestPark is committed to forging lasting partnerships with emerging growth companies and the investors who back them.  WestPark provides a comprehensive range of corporate finance services, including initial public offerings, reverse mergers, follow-on offerings, private placements and corporate finance advisory services. Additional information about WestPark Capital, Inc. is available at or at

About IsoRay, Inc.

IsoRay, Inc., through its subsidiary, IsoRay Medical, Inc., is the exclusive producer of Cesium-131 internal radiation therapy, which is expanding brachytherapy options throughout the body. Learn more about this innovative Richland, Washington company and explore the many benefits and uses of Cesium-131 by visiting


WestPark Capital, Inc.
Richard Rappaport, CEO
310) 843-9300

SOURCE WestPark Capital, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. WestPark Capital Announces $2.6 Million IsoRay Offering
2. Alexza Executes $15 million Working Capital Loan with Hercules Technology Growth Capital, Inc.
3. Concord Medical Announces Shareholder Resolutions Adopted at 2011 Annual General Meeting, Board and Management Changes
4. Physicians Capital Investments Announces Pedro Vergne-Marini, MD Named to Beckers ASC Review "350 People in the ASC Industry to Know"
5. Walmart Announces Generic Lipitor® (Atorvastatin Calcium Tablets) Available in Stores Today
6. Regeneron Announces Presentation Time Change at the 2011 Deutsche Bank BioFEST
7. Arbor Pharmaceuticals Announces Filing of First NDA
8. HASCO Medical Announces Approval to Acquire Certified Medical and Certified Auto of Ocala
9. Auxilium Pharmaceuticals, Inc. Announces First Patient Dosed in XIAFLEX® Study for Frozen Shoulder Syndrome
10. Forbes Announces IntegriChain in Top 20 on List of Americas Most Promising Companies
11. Kewaunee Scientific Announces Results for Second Quarter
Post Your Comments:
(Date:11/26/2015)... , November 26, 2015 ... the addition of the  "2016 Future ... European Therapeutic Drug Monitoring (TDM) Market: ... Intelligence, Emerging Opportunities"  report to their ... has announced the addition of the  ...
(Date:11/26/2015)... , November 26, 2015 ... of the "Radioimmunoassay Market by Type ... Pharmaceutical Industry, Academics, Clinical Diagnostic Labs), Application ... Forecast to 2020" report to their ... announced the addition of the "Radioimmunoassay ...
(Date:11/25/2015)...  Amgen (NASDAQ: AMGN ) today announced the ... the United States (U.S.) Food and ... to Humira ® (adalimumab). Amgen believes this submission ... FDA and represents Amgen,s first BLA submission using the ... M.D., executive vice president of Research and Development at ...
Breaking Medicine Technology:
(Date:11/26/2015)... ... November 26, 2015 , ... ... eReferral system for diagnostic imaging in the Waterloo region. Using the Ocean Platform, ... Medicine tests directly from their electronic medical record (EMR) without the need for ...
(Date:11/26/2015)... (PRWEB) , ... November 26, 2015 , ... ... of workshops to discuss bioavailability and the need to integrate dose form selection ... in collaboration with OBN, the membership organization supporting and bringing together the UK’s ...
(Date:11/26/2015)... (PRWEB) , ... November 26, 2015 , ... PRMA Plastic ... November 19, 2015, our surgeons performed their 6,000th free flap breast reconstruction surgery! , ... wake up every day excited to rebuild lives and it’s an honor to have ...
(Date:11/26/2015)... ... November 26, 2015 , ... Pixel Film Studios brings Final ... ProTrailer: Vintage. This newly styled ProTrailer pack comes with 30 all-new vintage-inspired designs, ... giving users limitless opportunities to stylize and create designs quickly and easily, all ...
(Date:11/26/2015)... ... November 26, 2015 , ... Indosoft Inc., developer and distributor of the ... to improve system efficiency and reliability. , The new Q-Suite 6 platform is based ... system avoids locking itself into a specific piece of software for many key components ...
Breaking Medicine News(10 mins):